Completed PHASE4 INTERVENTIONAL 2-arm NCT00612755

Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4

Open, Randomized, Multicenter Phase IV Study to Evaluate Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Patients Genotype 1 and/or 4

Sponsor: Hospital Clinico Universitario San Cecilio

Conditions HIV Infections Hepatitis C

Interventions Peginterferon alfa-2a + ribavirin

Updated 5 times since 2017 Last updated: Jan 29, 2008 Started: Oct 31, 2005 Primary completion: Jan 31, 2007 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00612755, this PHASE4 trial focuses on HIV Infections and Hepatitis C and remains completed. Sponsored by Hospital Clinico Universitario San Cecilio, it has been updated 5 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Clinico Universitario San Cecilio

Data source: Hospital Clinico Universitario San Cecilio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alcorcón, Spain , Barcelona, Spain , Cadiz, Spain , Granada, Spain , Jerez de la Frontera, Spain , L'Hospitalet de Llobregat, Spain , Las Palmas, Spain , Madrid, Spain , Palma de Mallorca, Spain , San Sebastián, Spain and 5 more locations